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Abstract Friedreich’s ataxia is an inherited neurological dis-
order characterised by mitochondrial dysfunction and in-
creased susceptibility to oxidative stress. At present, no ther-
apy has been shown to reduce disease progression. Strategies
being trialled to treat Friedreich’s ataxia include drugs that
improve mitochondrial function and reduce oxidative injury.
In addition, stem cells have been investigated as a potential
therapeutic approach. We have used siRNA-induced knock-
down of frataxin in SH-SY5Y cells as an in vitro cellular
model for Friedreich’s ataxia. Knockdown of frataxin protein
expression to levels detected in patients with the disorder was
achieved, leading to decreased cellular viability, increased sus-
ceptibility to hydrogen peroxide-induced oxidative stress,
dysregulation of key anti-oxidant molecules and deficiencies
in both cell proliferation and differentiation. Bone marrow
stem cells are being investigated extensively as potential treat-
ments for a wide range of neurological disorders, including
Friedreich’s ataxia. The potential neuroprotective effects of
bone marrow-derived mesenchymal stem cells were therefore
studied using our frataxin-deficient cell model. Soluble factors
secreted by mesenchymal stem cells protected against cellular
changes induced by frataxin deficiency, leading to restoration
in frataxin levels and anti-oxidant defences, improved survival
against oxidative stress and stimulated both cell proliferation
and differentiation down the Schwann cell lineage. The dem-
onstration that mesenchymal stem cell-derived factors can
restore cellular homeostasis and function to frataxin-
deficient cells further suggests that they may have potential
therapeutic benefits for patients with Friedreich’s ataxia.
Keywords Friedreich’s ataxia . Mesenchymal stem cells .
Frataxin . Oxidative stress
Introduction
Friedreich’s ataxia (FA) is a genetic disorder caused by a GAA
repeat expansion within the first intron of the frataxin gene
(FXN) and is characterised by a number of clinical manifesta-
tions, including cerebellar ataxia and cardiomyopathy [1]. This
expansion leads to reduced expression of frataxin, a mitochon-
drial protein the functions of which include iron chaperoning in
iron-sulphur cluster and heme biosynthesis, maintenance of
anti-oxidant defences and iron detoxification [2, 3]. The amount
of frataxin gene and protein expression in clinically symptom-
atic patients varies from approximately 5–35% of normal
levels. Furthermore, a correlation between reduced frataxin
levels (longer GAA expansions) and earlier-onset neurological
disease implies a role for frataxin in maintenance and protection
of neurons [4]. The precise subsequent mechanisms of cell
death and neurodegeneration remain the subject of active re-
search, with an increasing consensus suggesting that oxidative
damage plays a key role [5].
Cellular and in vivo models of frataxin deficiency show
increased susceptibility to damage from reactive oxygen and
nitrogen species, particularly hydrogen peroxide [6]. Cells
derived from patients with FA are known to have deficiencies
in defences against oxidative stress, and this is thought to be
one of the major causes of tissue injury in the disease [7].
Reduction in cellular frataxin has been associated with de-
creases in superoxide dismutase (SOD) activity and hydrogen
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peroxide-detoxifying enzymes [8, 9]. This failure of endoge-
nous anti-oxidant defences causes elevation in lipid peroxida-
tion, mitochondrial dysfunction and DNA injury, with subse-
quent cytotoxicity and tissue damage [10]. Thus, one potential
approach to reduce tissue injury in FA is to define therapies
that boost endogenous frataxin and/or anti-oxidant responses.
Mesenchymal stem cells (MSCs) are being investigated
extensively as potential treatments for a wide range of dis-
eases, not least neurological disorders. The mode of action
of stem cell-mediated neuroprotection is likely to be multifac-
torial, but boosting endogenous repair mechanisms in disease
states, including FA [7, 9, 11, 12], is a key area for research.
Indeed, increasing evidence implies the major mechanistic
neuroprotective role of MSCs is their capacity to secrete a
diverse range of potentially neuroprotective factors or through
anti-oxidant actions [13–15]. If stem cell therapies are to be-
come a viable therapeutic approach for central nervous system
(CNS) degeneration, a precise understanding of their effects
on neurons is required.
With this aim, we have modelled frataxin-knockdown in
SH-SY5Y cells to both further understand oxidative stress
mechanisms within frataxin-deficient cells and investigate
the potential anti-oxidant properties of MSC-secreted factors.
SH-SY5Y cell lines are composed of multipotent precursor
cells that give rise to distinct neural crest cell lineages and
have been widely used for studies of neurodegenerative dis-
orders [16]. The SH-SY5Y cell line may have particular rele-
vance to FA; cells affected in FA including neurons of the
dorsal root ganglion (DRG), satellite cells, Schwann cells
and axons of sensory nerves and dorsal spinal roots all derive
from the neural crest. Thus, pathophysiology of FA may be
attributed to defects in shared precursor cells [17]. Here, we
show that frataxin-deficient SH-SY5Y cells have reduced
anti-oxidant defences, increased sensitivity to hydrogen
peroxide-mediated toxicity and abnormalities in both cell pro-
liferation and differentiation. Furthermore, exposing frataxin-
deficient SH-SY5Y cells to MSC-secreted factors restores
frataxin expression, anti-oxidant homeostasis and cellular
function.
Materials and Methods
Bone Marrow Mononuclear Cell Isolation from Healthy
Control Patients
Bone marrow samples were obtained by an orthopaedic sur-
geon at Southmead Hospital, Bristol, UK, with informed writ-
ten consent and hospital ethic committee approval by the
North Bristol NHS trust research ethics committee. Bone mar-
row was taken at the time of total hip replacement surgery
from the femoral shaft and placed into a sterile 50-ml tube
containing 1000 IU heparin. Patients with a history of
malignancy, immune disorders or rheumatoid arthritis were
excluded from the study. Femoral shaft bone marrow donors
were healthy apart from osteoarthritis and were not receiving
drugs known to be associated with myelosuppression or bone
marrow failure.
Femoral shaft marrow samples were broken up with a scal-
pel and washed with Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma-Aldrich, Gillingham, UK) until remaining
material, the bone looked white at the bottom of the 50-ml
tube. All washings were pipetted into a new 50-ml tube and
kept for centrifugation. The suspension was centrifuged and
re-suspended in DMEM and overlaid onto an equal volume of
Lymphoprep (Axis-Shield, Dundee, UK; densi ty
1.077 ± 0.001 g/ml) and centrifuged at 600×g for 35 min at
room temperature to separate the mononuclear cells from neu-
trophils and red cells. The mononuclear cell layer was harvest-
ed and washed twice in DMEM.
Mesenchymal Stem Cell Culture
Mononuclear cells were isolated, centrifuged and re-
suspended in MSC medium consisting of DMEM with 10%
foetal calf serum (FCS) selected for the growth of MSCs
(Stem Cell Technologies, London, UK), 2% L-glutamine
and 1% penicillin and streptomycin (Sigma-Aldrich,
Gillingham, UK). For the primary culture, vented flasks
(25 cm2) containing 10 ml of MSC medium were seeded with
1 × 107 cells and then incubated in a humidified atmosphere at
37 °C containing 5% CO2. These cells were fed every week
with MSC medium by half medium exchange to remove non-
adherent haematopoietic cells until the adherent fibroblast-like
MSCs reached approximately 70% confluence. On reaching
confluence, the adherent cells were re-suspended using 0.25%
trypsin-EDTA (Sigma-Aldrich, Gillingham, UK) and re-
seeded at 2.25 × 105 cells per (75 cm2) flask into first passage.
Cultures were then incubated, fed every week with MSC me-
dium by half medium exchange and again trypsinised, a cell
count taken and re-seeded at 2.25 × 105 cells per flask
(75 cm2). Cell cultures were incubated at 37 °C containing
5% CO2. At 2–3 passage MSCs were phenotypically
characterised using cell surface marker expression and differ-
entiation protocols as described in previous studies from our
laboratory [15, 18, 19].
Mesenchymal Stem Cell Conditioned Medium
Confluent MSCs, at passages 3–5, were washed in DMEM
and cultured for 24 h in minimal base medium consisting of
DMEM (Stem Cell Technologies, London, UK) supplement-
ed with 1% insulin-free Sato (containing 100 μg/ml bovine
serum albumin, 100 μg/ml transferrin, 0.06 μg/ml progester-
one, 16 μg/ml putrescine, 0.04 μg/ml selenite, 0.04 μg/ml
thyroxine, 0.04 μg/ml tri-iodothryonine), 1% holo-transferrin,
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1% penicillin/streptomycin and 0.5% L-glutamine (Sigma-
Aldrich, Gillingham, UK). The medium was then removed
prior to being used within culture experiments. MSC condi-
tioned medium in this study was prepared from >10 indepen-
dent MSC samples.
SH-SY5Y Cell Culture
Human neuroblastoma SH-SY5Y cells (Obtained from
the European Col lec t ion of Authent ica ted Cel l
Cultures (ECACC)) were grown in SH-SY5Y growth medi-
um DMEM (glucose 4 g/l) (Sigma-Aldrich, UK) with 10%
FCS (Sigma-Aldrich, Gillingham, UK), 2% L-glutamine
(Sigma-Aldrich, Gillingham, UK) and 1% penicillin and
streptomycin (Sigma-Aldrich, Gillingham, UK). These cells
were fed every 48 h and passaged once the cells reached a
confluency of approximately 80%. Adherent cells were incu-
bated with 0.25% trypsin-EDTA (Sigma-Aldrich, Gillingham,
UK) at 37 °C with 5% CO2 for 5 min in order to dissociate
adherent cells from the culture flasks. Proteolysis by trypsin
was stopped with the addition of DMEM supplemented with
10% FCS. The dissociated cells were centrifuged with the SH-
SY5Y culture medium at 600×g for 10 min before being
counted and seeded into fresh culture flasks/wells. Cell cul-
tures were incubated at 37 °C containing 5% CO2. Cells were
not cultured past passage 25.
Transfection of SH-SY5Y Cells
Transfection of SH-SY5Y was carried out using Amaxa
Nucleofector cell line kit V (Lonza, Basel, Switzerland).
4 × 106 cells were transfected with FXN small interfering
RNA (siRNA) (diluted in water) (Applied Biosystems, UK)
according to the manufacturer’s instructions. The nucleofector
programme G-04 was chosen for high transfection efficiency.
Cells were subsequently re-suspended in DMEM/10% FCS/
2% L-glutamine and seeded into 6- or 96-well plates at a
density of 5 × 105 per well and 1 × 104 per well, respectively,
for further experimentation. For a mock-treated control, dis-
tilled water (H2O carrier transfected control) or scrambled
siRNA (Applied Biosystems, UK) was used in place of the
FXN siRNA.
SH-SY5Y Expansion and Differentiation
For expansion, transfected or non-transfected cells were
cultured for 24 h, trypsinised and re-seeded at 2 × 105 in a
6-welled plate. Cells were cultured in either 2× SH-SY5Y
growth medium/minimal medium (1:1) or 2× SH-SY5Y
growth medium/MSC conditioned medium (1:1). Medium
was replaced every 2 days and cells numerated after 8 days.
For differentiation, transfected or non-transfected cells
were cultured for 24 h, trypsinised and re-seeded at 2 × 105
in a 6-welled plate containing 10 μM retinoic acid (RA)
(Sigma-Aldrich) in 2× SH-SY5Y growth medium/minimal
medium (1:1) or 2× SH-SY5Y growth medium/MSC
conditioned medium (1:1) for 8 days. Differentiation medium
was replaced every 2 days. Control cells were treated
identically but with an equal volume of vehicle ethanol
(0.02%) in place of RA. Both SH-SY5Y differentiated
Neuronal (N type) and Schwann (S type) cells were identified
based on their distinct morphology.
Western Blotting
SH-SY5Y cells were lysed using Beadlyte cell signalling
universal lysis buffer (Upstate™, UK). To ensure there was
equal loading of cell lysates, the concentration of total protein
of each cell lysate sample was calculated using the Qubit®
Fluorometer and Quant-iT™ protein assay kit (Invitrogen,
UK) according to manufacturers’ instructions. Laemmli 2×
sample buffer (Invitrogen, UK) was added to the lysates and
then heated for 5 min at 95 °C. These samples were then run
on Tris-HCL 4–20% ready gels (Bio-Rad, UK). Following
transfer to a nitrocellulose membrane (Bio-Rad, UK) and
blocking in Tris-buffered saline/5% bovine serum albumin,
membranes were incubated in primary antibody overnight at
4 °C in Tris-buffered saline/5% bovine serum albumin. The
antibodies used were the following: anti-β-actin (1:5000;
Abcam, UK); rabbit anti-catalase (1:10,000; Abcam, UK);
mouse anti-human frataxin (which recognises a band
migrating at approximately 18 kDa corresponding to the
mature frataxin protein isoform (aa 56–210) (1:1000;
Millipore, UK) or mouse anti-human frataxin (1:1000
Abcam, UK); rabbit anti-glutathione peroxidase 1 (GPX)
(1:5000; Abcam, UK); anti-nuclear factor (erythroid-derived
2)-like 2 (Nrf2) (Santa Cruz; 1:3000), anti-peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC1a) (Santa Cruz; 1:3000); rabbit anti-superoxide
dismutase 1 (SOD1) (1:4000); and mouse anti-superoxide
dismutase 2 (SOD2) (1:4000; both Abcam, UK). For cell
signalling studies, antibodies used were: phospho-Akt
(Ser473); and total Akt (both 1:1000; Cell Signalling
Technology). Secondary antibodies: anti-rabbit or anti-
mouse horseradish peroxidase conjugated antibodies
(in Tris-buffered saline/5% bovine serum albumin; Abcam,
UK) were used to identify immunoreactivity. Visualisation
of specific protein expression patterns was performed by
chemiluminescence using either an EZ-ECL kit (Geneflow,
UK) or Amersham ECL Plus™ Western Blotting
Detection System (Amersham, UK) in conjunction with
a Biorad Universal III Bioplex imager. ImageJ soft-
ware™ was used for the densitometric analysis of the
western blot bands. β-actin expression was used as a
loading control in the western blot analysis.
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Assessment of Nitric Oxide or Hydrogen Peroxide
Cytotoxicity
After 48 h in culture, SH-SY5Y cells in 96-well plates were
exposed to experimental conditions. Medium was removed
from all wells, cells were washed twice in DMEM and mini-
mal medium or MSC conditioned medium containing the
nitric oxide donor, DETA-NONOate (ranging from 0 to
800 μM; Fluorochem, UK) or hydrogen peroxide (ranging
from 0 to 800 μM; Sigma-Aldrich, Gillingham, UK) was
added for 6 h. Evaluation of cell survival was carried out using
the MTT cell viability assay.
MTT Cell Viability Assay
The supernatant was removed and replaced with Hank’s bal-
anced salt solution (HBSS)/10% FCS containing 1 mg/ml
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT; Sigma-Aldrich, Gillingham, UK). Cells
were then incubated for 1 h at 37 °C, and subsequently, the
HBSS/10% FCS/MTT solution was removed by inverting the
plate and the plate left to dry. Dimethyl Sulfoxide (DMSO)
(Sigma-Aldrich, Gillingham, UK) was then added to each
well and the absorbance of the solution in each well read in
a plate reader at 540 nm. Cell survival was assessed as a ratio
of the amount of formazan production relative to the respec-
tive control. In all cases, control cultures grown throughout
the experimental period in minimal medium were analysed
and values for the experimental conditions divided by this
value, in order to standardise results between experiments.
Microscopy and Cell Quantification
Cells were visualised and images taken using aMotic AE2000
inverted phase contrast microscope, Moticam 10 camera and
Motic images plus 2.0 software (Motic). At least 5 indepen-
dent samples were included in the analyses. All cells were
counted within five randomly assigned set areas distributed
around the culture well.
Statistical Analysis
The analysis was performed usingGraphPad Prism (GraphPad
Software Inc., USA). For all tests, values of p < 0.05 were
considered statistically significant. At least three indepen-
dent samples from each group were included in the analy-
ses. Data between two groups were analysed using either
unpaired t tests or Mann-Whitney U tests. Statistical com-
parisons for over two groups were analysed using either
the Friedman test, one-way or two-way analysis of vari-
ance (ANOVA) with post hoc testing between groups
where appropriate. Data are represented as mean ± SEM.
Results
Transfection of SH-SY5Y Cells with FXN siRNA Results
in Decreased Frataxin Expression
Preliminary experiments were performed transfecting SH-
SY5Y cells using several concentrations of of FXN siRNA.
Utilising western blotting and protein band densitometry, it
was demonstrated that transfection using 100 or 400 pmol
FXN siRNA (diluted in H2O) resulted in a reduction in the
expression of the frataxin protein (Fig. 1a, b). 48 h post trans-
fection with 100 pmol FXN siRNA resulted in an approximate
20% reduction in frataxin protein expression (p < 0.05;
Fig. 1b). Transfection using 400 pmol FXN siRNA resulted
in a 15% reduction in frataxin levels after 24 h of culture
(p < 0.05; Fig. 1a) and 75% knockdown in frataxin protein
levels following 48 h in culture (p < 0.01; Fig. 1b). β-actin
was used as an internal western blot loading control. For all
further experimentations, transfection was carried out using
400 pmol FXN siRNA.
Transfection with FXN siRNA Decreases Survival
of SH-SY5Y Cells
The number of viable cells in each group was calculated as a
percentage normalised to a non-transfected control group.
Forty-eight hours following transfection, five random fields
per culture were counted and averaged. The transfection pro-
cess itself caused cell death as can be seen in the reduction of
live cells (approximate 20% reduction) in the H2O carrier or
scrambled siRNA transfected groups (Fig. 1c). A significantly
higher proportion of cell death was also seen amongst theFXN
siRNA transfected cells (approximate 40% reduction) com-
pared to either H2O carrier or scrambled siRNA transfected
controls (p < 0.001; Fig. 1c, d).
Sensitivity to Oxidative Stress
Sensitivity of FXN siRNA transfected SH-SY5Y cells to
oxidative stress was investigated using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viabili-
ty assay. Transfected cells were exposed to the nitric oxide
donor DETA-NONOate in minimal medium for 6 h at con-
centrations ranging from 0 to 800 μM. Cell survival decreased
with increasing concentrations of the nitric oxide donor. No
significant difference was seen between the FXN siRNA
transfected cells and the H2O carrier transfected control group
(p = 0.09; Fig. 2a). Cells were also exposed to hydrogen per-
oxide in minimal medium for 6 h at concentrations ranging
between 0 and 800 μM. Cell survival decreased with increas-
ing hydrogen peroxide concentrations. There was also a sig-
nificant difference between the FXN siRNA and H2O carrier
transfected groups; the cells transfected withFXN siRNAwere
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Fig. 2 Susceptibility to nitric oxide and hydrogen peroxide mediated
toxicity. Cell survival determined using an MTT viability assay in SH-
SY5Y cells transfected with FXN siRNA or H2O carrier (control)
following 6 h exposure to varying levels of (a) DETA-NONOate
(Nitric oxide) and (b) hydrogen peroxide. c Cell survival of SH-SY5Y
cells transfected with FXN siRNA exposed to minimal medium or MSC
conditionedmedium (MSC) and differing levels of hydrogen peroxide for
6 h. d Representative images of SH-SY5Y cells transfected with FXN
siRNA exposed tominimal medium orMSC conditionedmedium (MSC)
with/without 6 h exposure to 600 μM hydrogen peroxide. Results are
expressed as mean percentage value relative to control (0 μM hydrogen
peroxide). ± SEM; n = 3; groups were compared using 2-way ANOVA.
*** p < 0.001; ns not significant; Scale bar = 100 μm
Fig. 1 Frataxin expression in
SH-SY5Y cells after FXN siRNA
transfection. Western blotting
images and corresponding
densitometric analysis (integrated
density) demonstrating
expression of frataxin in SH-
SY5Y cells following transfection
using 100 or 400 pmol FXN
siRNA after (a) 24 h in culture or
(b) 48 h in culture. β-actin was
used as a loading control. Results
are expressed as mean percentage
relative to H2O carrier transfected
controls. c Percentage of SH-
SY5Y cell survival following
transfection with 400 pmol FXN
siRNA, scrambled
(Scram) siRNA or H2O carrier
(control) for 48 h. d
Representative images of SH-
SY5Y cells 48 h post-transfection
with 400 pmol FXN siRNA.
± SEM; n = 3; *p < 0.05;
**p < 0.01; ***p < 0.001; ns not
significant; scale bar = 100 μm
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more sensitive to hydrogen peroxide over the concentrations
tested (p < 0.001; Fig. 2b).
Neuroprotection of Frataxin-Deficient Cells by MSC
Conditioned Medium
The effects of MSC-secreted factors on the survival of FXN
siRNA transfected SH-SY5Y cells was next determined.
Cellular toxicitiy was mediated by exposing FXN siRNA
transfected cells to hydrogen peroxide at concentrations rang-
ing from 0 to 800 μM for 6 h in either minimal medium or
minimal medium conditioned by MSCs (MSC conditioned
medium). An MTT cell viability assay was performed. MSC
conditioned medium significantly increased cell survival from
hydrogen peroxide-mediated injury when compared to cells
exposed to hydrogen peroxide in minimal medium alone
(p < 0.001; Fig. 2c, d).
Expression of Anti-oxidant Enzymes
Forty-eight hours post transfection, H2O carrier or FXN
siRNA transfected SH-SY5Y cells were exposed to either
minimal medium or MSC-conditioned medium for 24 h.
Subsequently anti-oxidant enzyme expression was deter-
mined using western blotting and protein band densitometry.
To ensure equal loading of cell lysates, β-actin was used as a
loading control. Superoxide scavenging enzymes; SOD1 and
SOD2 catalyse the dismutation of reactive superoxide anions
into hydrogen peroxide and oxygen. Both SOD1 and SOD2
were expressed at significantly lower levels in the FXN siRNA
transfected cells compared to H2O carrier transfected controls
(p < 0.001; Fig. 3a, b). In addition, there was a significant
decrease in the levels of the hydrogen peroxide scavenging
enzyme catalase in FXN siRNA transfected cells compared to
H2O carrier transfected controls (p < 0.05; Fig. 3a, b).
Although lower, no significant change was observed for the
hydrogen peroxide scavenging enzyme glutathione peroxi-
dase 1 after transfection with FXN siRNA (p = 0.10;
Fig. 3a, b).
Exposure of FXN siRNA transfected cells to MSC condi-
tioned medium resulted in an amplification of both SOD1 and
SOD2 expression (when compared to base minimal medium
alone) to that approximately observed in H2O carrier
transfected controls (p < 0.01; Fig. 3a, b). Exposure of FXN
siRNA transfected cells to MSC conditioned medium also
resulted in a non-significant elevation in glutathione peroxi-
dase 1 expression and a significant amplification in the levels
of catalase by approximately 4-fold when compared to cells
cultured in minimal medium alone (being 2-fold greater than
expressed in H2O carrier transfected controls) (p < 0.001;
Fig. 3a, b).
Frataxin, Regulators of Cell Survival, and Anti-oxidant
Responses
Forty-eight hours post transfection, H2O carrier and FXN
siRNA transfected SH-SY5Y cells were exposed to either
minimal medium or MSC conditioned medium for 24 h.
Subsequently, protein expression was detected using western
blotting techniques. Image analysis using ImageJ software
calculated that, in the presence of MSC conditioned medium,
frataxin protein expression was significantly upregulated
Fig. 3 Expression of anti-oxidant enzymes. Western blotting images (a)
and corresponding densitometric analysis (integrated density) (b)
demonstrating protein expression of superoxide dismutase 1 (SOD1),
superoxide dismutase 2 (SOD2), glutathione peroxidase 1 (GPX) and
catalase in SH-SY5Y cells following transfection with H2O carrier
(control) or FXN siRNA with/without exposure to MSC conditioned
medium (MSC). Blots represent three separate cultures per condition.
β-actin was used as a loading control. Results are expressed as mean
percentage relative to H2O carrier transfected controls. ± SEM; n = 3;
*p < 0.05; **p < 0.01, ***p < 0.001; ns not significant
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fivefold in FXN siRNA transfected cells when compared to
cells cultured in minimal medium alone (p < 0.01) (Fig. 4a, b).
PGC1a and Nrf2 are key orchestrators of cellular anti-
oxidant responses and their expression is reduced in
frataxin-deficient cells [20, 21]. In line with other frataxin-
deficient models, FXN siRNA transfected cells had signifi-
cantly reduced protein levels of both PGC1a and Nrf2 when
compared to respective H2O carrier transfected controls
(p < 0.05; Fig. 4a, b). Conversely, exposure of FXN siRNA
transfected cells to MSC conditioned medium resulted in a
significant amplification in the levels of PGC1a and Nrf2 pro-
tein expression when compared to cells cultured in minimal
medium alone (p < 0.05; Fig. 4a, b).
We also studied the influence ofMSC conditioned medium
on the PI3kinase/Akt pathway in FXN siRNA transfected SH-
SY5Y cells. H2O carrier and FXN siRNA transfected cells
were incubated with MSC conditioned medium or minimal
medium for 6 h before lysis and analysis of phosphorylated-
Akt levels (relative to total Akt) using western blotting and
densitometric analysis. Phosphorylated-Akt levels did not
differ between FXN siRNA transfected cells and H2O carrier
transfected controls. However, MSC conditioned medium sig-
nificantly increased the levels of phosphorlyted-Akt in FXN
siRNA transfected cells relative to FXN siRNA transfected
cells cultured in minimal base medium alone (p < 0.05;
Fig. 4c, d).
Cell Proliferation and Differentiation
FXN siRNA transfected cells displayed a significantly slower
rate (approximately 50% decrease) in expansion over 8 days in
culture when compared to H2O carrier transfected controls
(p < 0.05; Fig. 5a, b). Under differentiation culture conditions
using exposure to retinoic acid, the largemajority of H2O carrier
transfected control cells over time became relatively polar, with
branching of long neurites, characteristic of the N-type
(Neuronal) phenotype (Fig. 6a, b). A significantly smaller
number (approx. 6%) of flat rounder cells were also observed,
typical of S-type (Schwann) cells (Fig. 6b). The frequency of N-
type cells after 8 days of culture, although lower, did not signif-
icantly differ between FXN siRNA and H2O carrier transfected
cells (p = 0.17; Fig. 6c), however, there was a significant
decrease in both the levels of S-type cells and subsequently
the S-type/N-type ratio in FXN siRNA transfected cells com-
pared to H2O carrier transfected controls (p < 0.05; Fig. 6c).
Investigating the effects of MSC conditioned medium on
both cell expansion and differentiation of FXN siRNA
transfected cells, we found addition of MSC conditioned me-
dium significantly increased the rate of cellular expansion
when compared to cells exposed to minimal medium alone
(p < 0.05; Fig. 5a, b). Equally, exposure to MSC conditioned
medium under differentiation conditions, the levels of both S-
type cells and the S-type/N-type ratio were significantly
Fig. 4 Expression of frataxin,
regulators of cell survival, and
anti-oxidant responses. Western
blotting images (a, c) and
corresponding densitometric
analysis (integrated density) (b, d)
(demonstrating protein
expression of frataxin;
peroxisome proliferator-activated
receptor gamma coactivator 1-
alpha (PGC1a); nuclear factor
(erythroid-derived 2)-like 2
(Nrf2); and phosphorylated-Akt
(phos-Akt) in SH-SY5Y cells
following transfection with H2O
carrier (control) or FXN siRNA
with/without exposure to MSC
conditioned medium (MSC).
Blots represent three separate
cultures per condition. β-actin or
total Akt were used as loading
controls. Results are expressed as
mean percentage relative to H2O
carrier transfected controls. ±
SEM; n = 3; *p < 0.05;
**p < 0.01, ***p < 0.001; ns not
significant
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increased and restored to those seen in the H2O carrier
transfected control group (p < 0.05; Fig. 6c, d). We found no
significant changes in either expansion or numbers of N- and
S-type cells in the H2O carrier transfected control group ex-
posed to MSC conditioned medium (data not shown).
Discussion
Oxidative damage and inhibition of mitochondrial function
may be key determinants of cellular damage in FA. Cells defi-
cient in frataxin have a greater sensitivity to oxidative stress and
Fig. 5 Cell expansion of FXN siRNA transfected SH-SY5Y cells. Cell
expansion (a) and representative images of SH-SY5Y cells 8 days post
transfection with H2O carrier control (control) or FXN siRNA with/
without exposure to MSC conditioned medium (MSC) (b). Results are
expressed as mean percentage relative to H2O carrier transfected controls.
± SEM; n = 5; *p < 0.05; Scale bar = 75 μm
Fig. 6 Differentiation of FXN siRNA transfected SH-SY5Y cells. a
Representative images of SH-SY5Y H2O carrier transfected controls
(Control) cultured for 8 days with or without addition of retinoic acid
(RA). b Images depicting cells with either an N-type or S-type morphol-
ogy. c The number N-type cells, S-type cells and the S-type/N-type ratio
following transfection with H2O carrier (control) or FXN siRNA and
differentiation with RA with/without exposure to MSC conditioned
medium (MSC). d Representative images of RA differentiated
SH-SY5Y cells following transfection with FXN siRNA with/without
exposure to MSC conditioned medium (MSC). Red arrows indicate the
position of S-type cells. ± SEM; n = 5; *p < 0.05; ns not significant; Scale
bars = 100 μm (a, d), 50 μm (b)
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also have an impaired ability to recruit anti-oxidant defences
[22, 23]. At present, there are no licenced therapies for disease
modification in FA. However, several strategies have been de-
veloped aiming to reduce the impact of frataxin deficiency,
including trialling agents that protect against oxidative damage
and mitochondrial respiratory chain defects (e.g. idebenone,
pioglitazone and deferiprone) [24, 25]. Strategies to increase
frataxin expression using drugs such as recombinant erythro-
poietin, interferon-gamma, nicotinamide, insulin-like growth
factor-1 (IGF-1), resveratrol and histone deacetylase enzyme
inhibitors (HDACi) are also being tested [26–31].
The human SH-SY5Y cell line originates from a neuroblas-
toma patient and these cells are widely used in neurological
studies. SH-SY5Y cells are multipotent precursor cells that
give rise to distinct neural crest cell lineages. The SH-SY5Y
cell line has particular relevance to FA, since many cells
affected in the disease derive from the neural crest, and the
pathophysiology of FA may be caused by defects to shared
precursor cells [17]. Three different cellular phenotypes of
SH-SY5Y cells have been identified: neuronal (N type);
Schwann (S type); and intermediary (I type). More specifical-
ly, SH-SY5Y cells have the ability to differentiate into neuro-
nal and Schwann cell progenitors, with prolonged exposure to
retinoic acid [32]. We have developed a cellular model of
frataxin deficiency in the SH-SY5Y cell line using frataxin
knockdown by siRNA technology. Since symptomatic
patients have less than 35% of frataxin levels compared to that
found in healthy controls [33], the aim was to develop a model
to accurately represent this. Forty-eight hours post exposure to
400 pmol of FXN specific siRNA down-regulated frataxin
protein levels to approximately 25% of that found in H2O
carrier transfected controls. Importantly, SH-SY5Y cells with
reduced frataxin expression showed a similar phenotype to
other FA models, namely: reduced cellular survival and
increased susceptibility to oxidative stress.
In line with previous reports in cellular and animal models
of FA, frataxin deficiency was associated with reduced protein
levels of PGC1a and Nrf2; both molecules being key orches-
trators of cellular anti-oxidant responses [34, 35]. Frataxin
knockdown also reduced expression of SOD1 and SOD2 in
SH-SY5Y cells. Cells derived from patients with FA have
previously demonstrated SOD deficiencies [7]. SOD1 and
SOD2 are both involved in dismutation of reactive superoxide
anions to prevent the build-up of the highly toxic metabolite
peroxynitrite. Interestingly, in this study, unlike previous re-
ports in FA patient cells [7], we did not find an increased
sensitivity to nitric oxide-mediated toxicity post frataxin
knockdown. A lack of increased sensitivity to nitric oxide
may be a possible consequence of alternate compensatory
anti-oxidant mechanisms.
FXN siRNA transfected cells exposed to hydrogen perox-
ide showed a significant reduction in survival compared to
transfected controls. Increased sensitivity to hydrogen
peroxide in frataxin-deficient cells has been previously noted
in FA models [6]. A possible explanation for this increased
sensitivity to hydrogen peroxide may be caused by the appar-
ent reductions in catalase levels. Reductions in hydrogen per-
oxide scavenging enzymes have been reported in cells derived
from patients with FA and are thought to contribute to in-
creased susceptibility to oxidative stress in these models [9].
Indeed, pathological studies of FA have demonstrated that
oxidative damage and increased sensitivity to oxidative stress
may be important contributors to the pathogenesis of the dis-
ease. In FA, low frataxin levels and defective anti-oxidant
defences causes iron overload through depletion of iron-
sulphur cluster synthesis [36]. Reactive free iron promotes
Fenton chemistry, producing superoxide and hydrogen perox-
ide, which in turn destroys more iron-sulphur clusters [36].
High levels of lipid peroxidation products, such as
malondialdehyde, which are formed by the action of oxygen
radicals (including hydroxyl (OH) and peroxynitrite (ONOO))
on lipid membranes are also observed in FA [37]. These reac-
tive aldehydes are themselves cytotoxic, having the capacity
to both inhibit DNA, RNA and protein synthesis and disrupt
membrane structures [38]. They can also perpetuate oxidative
stress by elevating mitochondrial reactive oxygen species and
inhibiting anti-oxidant enzymes [39], which may, in part, ex-
plain reductions in anti-oxidant molecules in frataxin-deficient
SH-SY5Y cells. Strategies to reduce oxidative injury may
therefore have important therapeutic implications for the
disease.
Bone marrow MSC transplantation regimens have been
studied as potential therapies for a number of neurological
disorders. Human MSCs have been shown to have a range of
neuroprotective and neuro-regenerative properties. Studies
have shown that MSCs release a plethora of potentially neuro-
protective growth factors including brain-derived neurotrophic
factor (BDNF), IGF-1, neurotrophin-3 [13, 15], stem cell fac-
tor (SCF) and granulocyte-colony stimulating factor (G-CSF)
[40], some of which have already shown promising therapeutic
potential for FA [31, 41, 42]. Regarding disorders characterised
by elevations in oxidative stress, MSCs can secrete anti-
oxidant molecules, which directly promote cellular survival
following oxidative stress by reducing toxic reactive oxygen
species; and may also induce nervous system cells to increase
endogenous production of anti-oxidant defences [18, 43].
In the current study, bone marrow-derived MSCs were
studied in order to determine if they secrete factors that may
offer protection against the cellular dysregulation induced by
frataxin deficiency. Importantly, in agreement with previous
reports [7, 9, 12], we showed that exposure of FXN-deficient
cells to MSC conditioned medium increased frataxin protein
expression. This is potentially due to the presence of several
known inducers of frataxin expression, including IGF-1, SCF
and G-CSF within MSC conditioned medium [42, 44].
Clinical therapies that are able to elevate frataxin levels, in
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theory, may be able to re-establish normal cellular function by
increasing frataxin levels to a threshold at or above that found
in asymptomatic heterozygous carriers of the GAA repeat
expansion [33]. Several agents have been tested for this pur-
pose, but there has been mixed success in their ability to in-
crease frataxin levels when tested in patients with FA [28–30,
45]. In line with increases in frataxin, exposure to MSC con-
ditioned medium also elevated the expression of molecules
associated with frataxin’s anti-oxidant functions including
PGC1a, Nrf2, superoxide dismuting enzymes (SOD 1 and 2)
and the hydrogen peroxide-scavenging enzyme catalase.
Since MSC conditioned medium protected SH-SY5Y cells
from hydrogen peroxide toxicity, the marked elevation in cat-
alase expression may be a major contributor to neuroprotec-
tion in the model. The increase in catalase induced by MSC
conditioned medium is of relevance, since hydrogen peroxide
scavenging has been shown to rescue frataxin deficiency in a
FA Drosophila model [6].
In an attempt to further identify molecular mechanisms
underlying the protective role of MSCs, we investigated
PI3kinase pathway signalling in FXN siRNA transfected cells.
We have previously shown that intact PI3kinase/Akt pathway
signalling is particularly important in the survival of human
FA-fibroblast cells against oxidative stress [7]. Moreover,
IGF-1, a potential therapeutic currently being tested in FA
[31], has been shown to normalise frataxin levels in frataxin-
deficient neurons and astrocytes through the Akt/mTOR sig-
nalling pathway [44]. Interestingly, SH-SY5Y cells deficient
in frataxin displayed no block in Akt signalling; however, in
the presence of MSC conditioned medium, a large increase in
Akt signalling was observed. MSC-mediated Akt activation in
frataxin-deficient cells may therefore play a critical role in
maintaining homeostasis and survival against cellular stress.
When investigating the effects of frataxin knockdown on
cellular proliferation and differentiation, we found a marked
reduction in both cell expansion and S-type (Schwann) cell
formation. Previous in vitro studies using human Schwann
cell lines show frataxin knockdown blocks cell cycle progres-
sion at G2M; this is followed by an upregulation of
inflammatory/apoptotic genes and cell loss [46]. Indeed, with
a deficient anti-oxidant system, the build-up of peroxynitrite
and subsequent increase in lipid peroxidation products can
lead to inhibition of DNA synthesis [38], thus a block in cell
proliferation. Pathologically, lack of myelination of large sen-
sory axons and loss of dorsal root ganglia cells is found in
patients with FA [47]. Myelinating Schwann cells help main-
tain axon integrity, thus several studies have suggested that
Schwann cells could be defective in FA and that degeneration
of peripheral neurons occurs as a secondary consequence [46,
48]. Post-mortem analysis of sural nerves of patients who had
FA shows a lack of myelinated fibres (hypomyelination)
whereas axons are present in normal numbers [48].
Histological investigations on the dorsal roots in post-
mortem samples also show differences in the myelination of
thin fibres and fewer numbers of Schwann cells [48]. This
provides evidence towards possible defective Schwann cells
or Schwann cell precursors in FA [17], as was also apparent in
the frataxin-deficient SH-SY5Y cell model. Exposure toMSC
conditioned medium significantly reversed the inability of
frataxin-deficient SH-SY5Y cells to differentiate down the
S-type cell lineage. MSCs are known to produce several fac-
tors recognised for aiding differentiation of SH-SY5Y cells,
including both BDNF and IGF-1 [49, 50]. MSCs can also
promote cell survival and proliferation of Schwann cells
in vitro, and in vivo stimulate peripheral nerve repair through
increased the generation of Schwann cells [51]. Together, our
data suggest that MSCs may have the therapeutic capacity to
help stimulate the maturation and differentiation of Schwann
cells to aid myelin/axonal repair in FA.
Conclusion
In conclusion, we have used frataxin knockdown in SH-SY5Y
cells as a cellular model for FA. FXN siRNA transfected SH-
SY5Y cells have proved to be a useful model for FA since
many of the biochemical properties of true FA patient-derived
cells are replicated. Knockdown of frataxin expression to 25%
of that seen in transfected controls was achieved and the phe-
notype of cells revealed (i) decreased cellular viability, (ii)
increased susceptibility to hydrogen peroxide-induced oxida-
tive stress, (iii) reduction in expression of key anti-oxidant
molecules and (iv) a deficiency in both cell proliferation and
differentiation. The FA cellular model was used to study po-
tential neuroprotective effects of MSCs. We show MSC-
secreted factors were able to protect against the cellular dys-
regulation induced by frataxin deficiency. The demonstration
that factors produced by MSCs can regulate frataxin expres-
sion and restore cellular homeostasis suggests that they may
have potential therapeutic benefits for patients with FA.
Acknowledgments K.K, N.S and A.W received a research grant from
Medical Research Council (grant number: MR/J012580/1).
This work was supported by the Medical Research Council (grant
number: MR/J012580/1).
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflicts of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
Cerebellum (2017) 16:840–851 849
References
1. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M,
Cavalcanti F, et al. Friedreich’s ataxia: autosomal recessive disease
caused by an intronic GAA triplet repeat expansion. Science.
1996;271:1423–7.
2. Gakh O, Park S, Liu G, Macomber L, Imlay JA, Ferreira GC, et al.
Mitochondrial iron detoxification is a primary function of frataxin
that limits oxidative damage and preserves cell longevity. HumMol
Genet. 2006;15:467–79.
3. Babady NE, Carelle N, Wells RD, Rouault TA, Hirano M, Lynch
DR, et al. Advancements in the pathophysiology of Friedreich’s
ataxia and new prospects for treatments. Mol Genet Metab.
2007;92:23–35.
4. Monros E, Molto MD, Martinez F, Canizares J, Blanca J, Vilchez
JJ, et al. Phenotype correlation and intergenerational dynamics of
the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet.
1997;61:101–10.
5. Pandolfo M. Drug insight: antioxidant therapy in inherited ataxias.
Nature clinical practice. 2008;4:86–96.
6. Anderson PR, Kirby K, OrrWC, Hilliker AJ, Phillips JP. Hydrogen
peroxide scavenging rescues frataxin deficiency in a Drosophila
model of Friedreich’s ataxia. Proc Natl Acad Sci U S A.
2008;105:611–6.
7. Dey R, Kemp K, Gray E, Rice C, Scolding N, Wilkins A. Human
mesenchymal stem cells increase anti-oxidant defences in cells de-
rived from patients with Friedreich's ataxia. Cerebellum. 2012;11:
861–71.
8. Irazusta V, Obis E, Moreno-Cermeno A, Cabiscol E, Ros J, Tamarit
J. Yeast frataxin mutants display decreased superoxide dismutase
activity crucial to promote protein oxidative damage. Free Radic
Biol Med. 2010;48:411–20.
9. Kemp K, Mallam E, Hares K, Witherick J, Scolding N, Wilkins A.
Mesenchymal stem cells restore frataxin expression and increase
hydrogen peroxide scavenging enzymes in Friedreich ataxia fibro-
blasts. PLoS One. 2011;6:e26098.
10. Abeti R, Uzun E, Renganathan I, Honda T, Pook MA, Giunti P.
Targeting lipid peroxidation and mitochondrial imbalance in
Friedreich’s ataxia. Pharmacological research: the official journal
of the Italian Pharmacological Society. 2015;99:344–50.
11. Jones J, Estirado A, Redondo C, Martinez S. Stem cells from
wildtype and Friedreich’s ataxia mice present similar neuroprotec-
tive properties in dorsal root ganglia cells. PLoS One. 2013;8:
e62807.
12. Jones J, Estirado A, Redondo C, Pacheco-Torres J, Sirerol-Piquer
MS, Garcia-Verdugo JM, et al. Mesenchymal stem cells improve
motor functions and decrease neurodegeneration in ataxic mice.
Mol Ther. 2015;23:130–8.
13. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG.
Human mesenchymal stem cell subpopulations express a variety of
neuro-regulatory molecules and promote neuronal cell survival and
neuritogenesis. Exp Neurol. 2006;198:54–64.
14. Lanza C, Morando S, Voci A, Canesi L, Principato MC, Serpero LD,
et al. Neuroprotective mesenchymal stem cells are endowed with a
potent antioxidant effect in vivo. J Neurochem. 2009;110:1674–84.
15. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N.
Human bone marrow-derived mesenchymal stem cells secrete
brain-derived neurotrophic factor which promotes neuronal surviv-
al in vitro. Stem Cell Res. 2009;3:63–70.
16. Kovalevich J, Langford D. Considerations for the use of SH-SY5Y
neuroblastoma cells in neurobiology. Methods Mol Biol.
2013;1078:9–21.
17. Morral JA, Davis AN, Qian J, Gelman BB, Koeppen AH.
Pathology and pathogenesis of sensory neuropathy in Friedreich’s
ataxia. Acta Neuropathol. 2010;120:97–108.
18. Kemp K, Hares K, Mallam E, Heesom KJ, Scolding N, Wilkins A.
Mesenchymal stem cell-secreted superoxide dismutase promotes
cerebellar neuronal survival. J Neurochem. 2010;114:1569–80.
19. Mallam E, Kemp K, Wilkins A, Rice C, Scolding N.
Characterization of in vitro expanded bone marrow-derived mes-
enchymal stem cells from patients with multiple sclerosis. Mult
Scler. 2010;16:909–18.
20. Shan Y, Schoenfeld RA, Hayashi G, Napoli E, Akiyama T, Iodi
Carstens M, et al. Frataxin deficiency leads to defects in expression
of antioxidants and Nrf2 expression in dorsal root ganglia of the
Friedreich’s ataxia YG8R mouse model. Antioxid Redox Signal.
2013;19:1481–93.
21. Sandi C, Sandi M, Jassal H, Ezzatizadeh V, Anjomani-Virmouni S,
Al-Mahdawi S, et al. Generation and characterisation of Friedreich
ataxia YG8R mouse fibroblast and neural stem cell models. PLoS
One. 2014;9
22. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, Taroni F,
et al. The Friedreich’s ataxia mutation confers cellular sensitivity to
oxidant stress which is rescued by chelators of iron and calcium and
inhibitors of apoptosis. Hum Mol Genet. 1999;8:425–30.
23. Chantrel-Groussard K, Geromel V, Puccio H, Koenig M, Munnich
A, Rotig A, et al. Disabled early recruitment of antioxidant defenses
in Friedreich’s ataxia. Hum Mol Genet. 2001;10:2061–7.
24. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH.
Neurological effects of high-dose idebenone in patients with
Friedreich’s ataxia: a randomised, placebo-controlled trial.
Lancet Neurol. 2007;6:878–86.
25. Goncalves S, Paupe V, Dassa EP, Rustin P. Deferiprone targets
aconitase: implication for Friedreich's ataxia treatment. BMC
Neurol. 2008;8:20.
26. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-
Mojdehkar B. Friedreich’s ataxia: clinical pilot trial with recombi-
nant human erythropoietin. Ann Neurol. 2007;62:521–4.
27. Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, et al.
Two new pimelic diphenylamide HDAC inhibitors induce
sustained frataxin upregulation in cells from Friedreich’s ataxia pa-
tients and in a mouse model. PLoS One. 2010;5:e8825.
28. Libri V, Yandim C, Athanasopoulos S, Loyse N, Natisvili T, Law
PP, et al. Epigenetic and neurological effects and safety of high-
dose nicotinamide in patients with Friedreich’s ataxia: an explorato-
ry, open-label, dose-escalation study. Lancet. 2014;384:504–13.
29. Yiu EM, Tai G, Peverill RE, Lee KJ, Croft KD, Mori TA, et al. An
open-label trial in Friedreich ataxia suggests clinical benefit with
high-dose resveratrol, without effect on frataxin levels. J Neurol.
2015;262:1344–53.
30. Marcotulli C, Fortuni S, Arcuri G, Tomassini B, Leonardi L, Pierelli
F, et al. GIFT-1, a phase IIa clinical trial to test the safety and
efficacy of IFNgamma administration in FRDA patients. Neurol
Sci. 2016;37:361–4.
31. Sanz-Gallego I, Torres-Aleman I, Arpa J. IGF-1 in Friedreich's
ataxia - proof-of-concept trial. Cerebellum Ataxias. 2014;1:10.
32. Bell N, Hann V, Redfern CP, Cheek TR. Store-operated
Ca(2+) entry in proliferating and retinoic acid-differentiated
N- and S-type neuroblastoma cells. Biochim Biophys Acta.
1833;2013:643–51.
33. Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M,
Monticelli A, et al. Real time PCR quantification of frataxin mRNA
in the peripheral blood leucocytes of Friedreich ataxia patients and
carriers. J Neurol Neurosurg Psychiatry. 2004;75:1061–3.
34. Paupe V, Dassa EP, Goncalves S, Auchere F, LonnM,Holmgren A,
et al. Impaired nuclear Nrf2 translocation undermines the oxidative
stress response in Friedreich ataxia. PLoS One. 2009;4:e4253.
35. Marmolino D, Manto M, Acquaviva F, Vergara P, Ravella A,
Monticelli A, et al. PGC-1alpha down-regulation affects the anti-
oxidant response in Friedreich's ataxia. PLoS One. 2010;5:e10025.
850 Cerebellum (2017) 16:840–851
36. Bayot A, Santos R, Camadro JM, Rustin P. Friedreich’s
ataxia: the vicious circle hypothesis revisited. BMC Med.
2011;9:112.
37. Emond M, Lepage G, Vanasse M, Pandolfo M. Increased levels
of plasma malondialdehyde in Friedreich ataxia. Neurology.
2000;55:1752–3.
38. Matveychuk D, Dursun SM, Wood PL, Baker GB. Reactive alde-
hydes and neurodegenerative disorders. Klin Psikofarmakol B.
2011;21:277–88.
39. Long J, Liu C, Sun L, Gao H, Liu J. Neuronal mitochondrial tox-
icity of malondialdehyde: inhibitory effects on respiratory function
and enzyme activities in rat brain mitochondria. Neurochem Res.
2009;34:786–94.
40. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson
SL. Human marrow-derived mesenchymal stem cells (MSCs) ex-
press hematopoietic cytokines and support long-term hematopoie-
sis when differentiated toward stromal and osteogenic lineages. J
Hematother Stem Cell Res. 2000;9:841–8.
41. Katsu-Jimenez Y, Loria F, Corona JC, Diaz-Nido J. Gene transfer of
brain-derived neurotrophic factor (BDNF) prevents neurodegener-
ation triggered by FXN deficiency. Mol Ther. 2016;24:877–89.
42. Kemp KC, Cerminara N, Hares K, Redondo J, Cook AJ, Haynes
HR, et al. Cytokine therapy-mediated neuroprotection in a
Friedreich's ataxia mouse model. Ann Neurol. 2017;81:212–26.
43. Kemp K, Gray E, Mallam E, Scolding N, Wilkins A. Inflammatory
cytokine induced regulation of superoxide dismutase 3 expression
by humanmesenchymal stem cells. Stem Cell Rev. 2010;6:548–59.
44. Franco C, Fernandez S, Torres-Aleman I. Frataxin deficiency un-
veils cell-context dependent actions of insulin-like growth factor I
on neurons. Mol Neurodegener. 2012;7:51.
45. Mariotti C, Fancellu R, Caldarazzo S, Nanetti L, Di Bella D,
Plumari M, et al. Erythropoietin in Friedreich ataxia: no effect
on frataxin in a randomized controlled trial. Movement disor-
ders: official journal of the Movement Disorder Society.
2012;27:446–9.
46. Lu C, Schoenfeld R, Shan Y, Tsai HJ, Hammock B, Cortopassi G.
Frataxin deficiency induces Schwann cell inflammation and death.
Biochim Biophys Acta. 1792;2009:1052–61.
47. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron
diseases with peroneal muscular atrophy. I. Neurologic, genetic,
and electrophysiologic findings in hereditary polyneuropathies.
Arch Neurol. 1968;18:603–18.
48. Koeppen AH,Morral JA, Davis AN, Qian J, Petrocine SV, Knutson
MD, et al. The dorsal root ganglion in Friedreich’s ataxia. Acta
Neuropathol. 2009;118:763–76.
49. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, et al.
Sequential treatment of SH-SY5Y cells with retinoic acid and brain-
derived neurotrophic factor gives rise to fully differentiated, neuro-
trophic factor-dependent, human neuron-like cells. J Neurochem.
2000;75:991–1003.
50. Dwane S, Durack E, Kiely PA. Optimising parameters for the dif-
ferentiation of SH-SY5Y cells to study cell adhesion and cell mi-
gration. BMC Res Notes. 2013;6:366.
51. Wang J, Ding F, Gu Y, Liu J, Gu X. Bone marrow mesen-
chymal stem cells promote cell proliferation and neurotroph-
ic function of Schwann cells in vitro and in vivo. Brain Res.
2009;1262:7–15.
Cerebellum (2017) 16:840–851 851
